The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment can revert or arrest progression of this disease. AD pathology is characterized by the accumulation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain. Genetic data, as well as autopsy and neuroimaging studies in patients with AD, indicate that Aβ plaque deposition precedes cortical tau pathology. Because Aβ accumulation has been considered the initial insult that drives both the accumulation of tau pathology and tau-mediated neurodegeneration in AD, the development of AD therapeutics has focused mostly on removing Aβ from the brain. However, striking preclinical evidence from AD mouse models and patient-derived human induced pluripotent stem cell models indicates that tau pathology can progress independently of Aβ accumulation and arises downstream of genetic risk factors for AD and aberrant metabolic pathways. This Review outlines novel insights from preclinical research that implicate apolipoprotein E, the endocytic system, cholesterol metabolism and microglial activation as Aβ-independent regulators of tau pathology. These factors are discussed in the context of emerging findings from clinical pathology, functional neuroimaging and other approaches in humans. Finally, we discuss the implications of these new insights for current Aβ-targeted strategies and highlight the emergence of novel therapeutic strategies that target processes upstream of both Aβ and tau.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
PDZD8-deficient mice manifest behavioral abnormalities related to emotion, cognition, and adaptation due to dyslipidemia in the brain
Molecular Brain Open Access 19 January 2023
Molecular Neurodegeneration Open Access 04 January 2023
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
Alzheimer's Research & Therapy Open Access 24 September 2022
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hardy, J. & Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci. 12, 383–388 (1991).
Selkoe, D. J. The molecular pathology of Alzheimer’s disease. Neuron 6, 487–498 (1991).
Ringman, J. M. et al. Neuropathology of autosomal dominant Alzheimer disease in the National Alzheimer Coordinating Center Database. J. Neuropathol. Exp. Neurol. 75, 284–290 (2016).
Gordon, B. A. et al. Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers. Brain 142, 1063–1076 (2019).
Quiroz, Y. T. et al. Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol. 75, 548–556 (2018).
Schöll, M. et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Brain 140, 2286–2294 (2017).
Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).
De Strooper, B. & Karran, E. The cellular phase of Alzheimer’s disease. Cell 164, 603–615 (2016).
Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 322–333 (2014).
Ostrowitzki, S. et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res. Ther. 9, 95 (2017).
Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer’s Disease. N. Engl. J. Med. 378, 321–330 (2018).
Roche. Roche to discontinue phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer’s disease (AD) - other company programmes in AD continue. Roche https://www.roche.com/media/releases/med-cor-2019-01-30.htm (2019).
Kemp, A. Update on phase III clinical trials of lanabecestat for Alzheimer’s disease. AstraZeneca https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html (2018).
Henley, D. et al. Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease. N. Engl. J. Med. 380, 1483–1485 (2019).
Egan, M. F. et al. Randomized trial of verubecestat for prodromal Alzheimer’s disease. N. Engl. J. Med. 380, 1408–1420 (2019).
Eisai. Eisai and Biogen to discontinue phase III clinical studies of BACE inhibitor elenbecestat in early Alzheimer’s disease. Esai http://eisai.mediaroom.com/2019-09-13-Eisai-And-Biogen-To-Discontinue-Phase-III-Clinical-Studies-Of-BACE-Inhibitor-Elenbecestat-In-Early-Alzheimers-Disease (2019).
Panza, F., Lozupone, M., Logroscino, G. & Imbimbo, B. P. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 15, 73–88 (2019).
Biogen. Biogen and Eisai to discontinue phase 3 ENGAGE and EMERGE trials of aducanumab in Alzheimer’s disease. Biogen http://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials (2019).
Biogen. Biogen plans regulatory filing for aducanumab in Alzheimer’s disease based on new analysis of larger dataset from phase 3 studies. Biogen http://investors.biogen.com/news-releases/news-release-details/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease (2019).
Musiek, E. S. & Holtzman, D. M. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. Nat. Neurosci. 18, 800–806 (2015).
Buckner, R. L. et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 25, 7709–7717 (2005).
Grothe, M. J. et al. In vivo staging of regional amyloid deposition. Neurology 89, 2031–2038 (2017).
Thal, D. R., Rüb, U., Orantes, M. & Braak, H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791–1800 (2002).
Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960–969 (2011).
Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).
Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79, 110–119 (2016). This is one of the earliest cross-sectional tau PET studies to show that tau pathology increases with advancing age and AD progression, and corresponds to Braak staging of NFT pathology.
Schöll, M. et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971–982 (2016).
Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).
Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924–1938 (2015). This large meta-analysis provides prevalence estimates of Aβ positivity in cognitively normal persons and patients with MCI.
Jack, C. R. Jr. & Holtzman, D. M. Biomarker modeling of Alzheimer’s disease. Neuron 80, 1347–1358 (2013).
Altmann, A. et al. Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain 138, 3734–3746 (2015).
Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 139, 1551–1567 (2016). This study shows that tau PET signal patterns, but not Aβ PET signal patterns, correlate with sites of neurodegeneration and domain-specific cognitive impairment.
Lowe, V. J. et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia. Brain 141, 271–287 (2018).
Ossenkoppele, R. et al. Discriminative accuracy of 18F-flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151–1162 (2018).
Schwarz, A. J. et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 139, 1539–1550 (2016). This study shows that tau PET can be used in vivo to replicate Braak staging of NFT pathology.
Ossenkoppele, R. et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology 92, e601–e612 (2019).
Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Morris, J. C. & Hassenstab, J. J. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 91, e859–e866 (2018).
Bejanin, A. et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain 140, 3286–3300 (2017).
Hanseeuw, B. J. et al. Fluorodeoxyglucose metabolism associated with tau–amyloid interaction predicts memory decline. Ann. Neurol. 81, 583–596 (2017).
LaPoint, M. R. et al. The association between tau PET and retrospective cortical thinning in clinically normal elderly. Neuroimage 157, 612–622 (2017).
Jack, C. R. et al. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study. Lancet Neurol. 16, 435–444 (2017).
Jack, C. R. et al. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain 142, 3230–3242 (2019).
Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755–766 (2014).
Duyckaerts, C. et al. PART is part of Alzheimer disease. Acta Neuropathol. 129, 749–756 (2015).
Braak, H. & Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351–357 (1997).
Price, J. L. & Morris, J. C. Tangles and plaques in nondemented aging and ‘preclinical’ Alzheimer’s disease. Ann. Neurol. 45, 358–368 (1999).
Cho, H. et al. Progressive tau accumulation in Alzheimer’s disease: two-year follow-up study. J. Nucl. Med. 60, 1611–1621 (2019).
Harrison, T. M. et al. Longitudinal tau accumulation and atrophy in aging and Alzheimer disease. Ann. Neurol. 85, 229–240 (2019).
Jack, C. R. et al. Longitudinal tau PET in ageing and Alzheimer’s disease. Brain 141, 1517–1528 (2018). This pioneering longitudinal tau PET study shows progressive tau accumulation in Aβ-positive cognitively normal persons (0.5% annually) and individuals with clinical AD (3.0% annually).
Pontecorvo, M. J. et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain 142, 1723–1735 (2019).
Raj, A. et al. Network diffusion model of progression predicts longitudinal patterns of atrophy and metabolism in Alzheimer’s disease. Cell Rep. 10, 359–369 (2015).
Jacobs, H. I. L. et al. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat. Neurosci. 21, 424–431 (2018).
Small, S. A. & Duff, K. Linking Aβ and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuron 60, 534–542 (2008). This review presents the dual-cascade hypothesis of AD.
Di Paolo, G. & Kim, T.-W. Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat. Rev. Neurosci. 12, 284–296 (2011).
Liu, C.-C., Liu, C.-C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106–118 (2013).
Guerreiro, R., Brás, J. & Hardy, J. SnapShot: genetics of Alzheimer’s disease. Cell 155, 968.e1 (2013).
Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat. Genet. 51, 404–413 (2019).
Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 51, 414–430 (2019).
Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C. & Sheng, M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 91, 328–340 (2016).
Chan, R. B. et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 287, 2678–2688 (2012).
Hutter-Paier, B. et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron 44, 227–238 (2004). This study shows that cholesteryl esters can drive accumulation of Aβ pathology in AD mice and that ACAT inhibitors have potential utility in the treatment of AD.
Puglielli, L. et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide. Nat. Cell Biol. 3, 905–912 (2001).
Simons, M. et al. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 6460–6464 (1998).
van der Kant, R. et al. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-β in iPSC-derived Alzheimer’s disease neurons. Cell Stem Cell 24, 363.e9–375.e9 (2019). This study uses hiPSC-derived AD neurons to show that cholesteryl esters drive the accumulation of Aβ and phosphorylated tau through correlated but independent mechanisms.
Barrett, P. J. et al. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168–1171 (2012).
Shibuya, Y. et al. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer’s disease mouse and reduces human P301L-tau content at the presymptomatic stage. Neurobiol. Aging 36, 2248–2259 (2015).
Boimel, M. et al. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol. 68, 314–325 (2009).
Sepulcre, J. et al. Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat. Med. 165, 3 (2018). This neurogenetic study shows that tau spread is associated with the expression of genes involved in axonal function, that Aβ spread is associated with the expression of genes involved in dendritic function and that the spreading patterns of both tau and Aβ are linked to the expression of genes involved in lipid metabolism.
van der Kant, R. & Goldstein, L. S. B. Cellular functions of the amyloid precursor protein from development to dementia. Dev. Cell 32, 502–515 (2015).
Sisodia, S. S. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl Acad. Sci. USA 89, 6075–6079 (1992).
Sannerud, R. et al. ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1. Proc. Natl Acad. Sci. USA 108, E559–E568 (2011).
Xiao, Q. et al. Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J. Biol. Chem. 287, 21279–21289 (2012).
Kanatsu, K. et al. Decreased CALM expression reduces Aβ42 to total Aβ ratio through clathrin-mediated endocytosis of γ-secretase. Nat. Commun. 5, 3386 (2014).
Ubelmann, F. et al. Bin1 and CD2AP polarise the endocytic generation of beta-amyloid. EMBO Rep. 18, 102–122 (2017).
Miyagawa, T. et al. BIN1 regulates BACE1 intracellular trafficking and amyloid-β production. Hum. Mol. Genet. 25, 2948–2958 (2016).
Andersen, O. M., Rudolph, I.-M. & Willnow, T. E. Risk factor SORL1: from genetic association to functional validation in Alzheimer’s disease. Acta Neuropathol. 132, 653–665 (2016).
Holstege, H. et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer’s disease: a clinical interpretation strategy. Eur. J. Hum. Genet. 25, 973–981 (2017).
Mecozzi, V. J. et al. Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol. 10, 443–449 (2014). This revolutionary biochemical study uses in silico screening to discover a small molecule that is capable of stabilizing the retromer complex.
Offe, K. et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J. Neurosci. 26, 1596–1603 (2006).
Muhammad, A. et al. Retromer deficiency observed in Alzheimer’s disease causes hippocampal dysfunction, neurodegeneration, and Aβ accumulation. Proc. Natl Acad. Sci. USA 105, 7327–7332 (2008).
Sartori, M. et al. BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with tau through Thr348 phosphorylation. Acta Neuropathol. 25, 5446–5422 (2019).
Lasorsa, A. et al. Structural basis of tau interaction with BIN1 and regulation by tau phosphorylation. Front. Mol. Neurosci. 11, 421 (2018).
Chapuis, J. et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol. Psychiatry 18, 1225–1234 (2013). This study shows that BIN1 regulates tau-mediated neurotoxicity in different AD model systems and that BIN1 polymorphisms are correlated with tau pathology but not with Aβ load in the AD brain.
Glennon, E. B. C. et al. BIN1 is decreased in sporadic but not familial Alzheimer’s disease or in aging. PLOS ONE 8, e78806 (2013).
Andrew, R. J. et al. Reduction of the expression of the late-onset Alzheimer’s disease (AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model. J. Biol. Chem. 294, 4477–4487 (2019).
Franzmeier, N., Rubinski, A., Neitzel, J. & Ewers, M., Alzheimer’s Disease Neuroimaging Initiative (ADNI). The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. Nat. Commun. 10, 1766 (2019).
Moreau, K. et al. PICALM modulates autophagy activity and tau accumulation. Nat. Commun. 5, 4998 (2014).
Young, J. E. et al. Stabilizing the retromer complex in a human stem cell model of Alzheimer’s disease reduces tau phosphorylation independently of amyloid precursor protein. Stem Cell Rep. 10, 1046–1058 (2018). This study of hiPSC-derived AD neurons shows that retromer stabilization decreases Aβ and p-tau levels through correlated but independent mechanisms.
Liu, L. et al. Glial Lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. Cell 160, 177–190 (2015).
Liu, L., MacKenzie, K. R., Putluri, N., Maletić-Savatić, M. & Bellen, H. J. The glia-neuron lactate shuttle and elevated ROS promote lipid synthesis in neurons and lipid droplet accumulation in glia via APOE/D. Cell Metab. 26, 719.e6–737.e6 (2017).
Mauch, D. H. et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354–1357 (2001).
Mattsson, N. et al. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer’s disease. Alzheimers Dement. 14, 913–924 (2018).
Corder, E. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923 (1993).
Raichlen, D. A. & Alexander, G. E. Exercise, APOE genotype, and the evolution of the human lifespan. Trends Neurosci. 37, 247–255 (2014).
Mahley, R. W., Weisgraber, K. H. & Huang, Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J. Lipid Res. 50, S183–S188 (2009).
Huang, Y.-W. A., Zhou, B., Wernig, M. & Südhof, T. C. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Aβ secretion. Cell 168, 427.e21–441.e21 (2017).
Dafnis, I. et al. ApoE isoforms and carboxyl-terminal-truncated apoE4 forms affect neuronal BACE1 levels and Aβ production independently of their cholesterol efflux capacity. Biochem. J. 475, 1839–1859 (2018).
Grothe, M. J. et al. Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. Neurology 88, 569–576 (2017).
Wang, C. et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat. Med. 24, 647–657 (2018). This study uses hiPSC-derived neurons of different APOE genotypes to show that ApoEε4 increases both Aβ and p-tau through independent pathways, and that these effects can be rescued by treatment with small molecules that correct the structure of ApoEε4.
Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523–527 (2017). This elegant mouse study shows that the ApoE*4 genotype affects tau pathology in the absence of Aβ pathology.
Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 22–35 (2015).
Lin, Y.-T. et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron 98, 1141.e7–1154.e7 (2018). This study characterizes gene-edited ApoEε3 and ApoEε4 hiPSC-derived neurons, astrocytes and microglia and demonstrates that the APOE*4 genotype suffices to render microglia more prone to inflammatory phenotypes.
Nuriel, T. et al. The endosomal–lysosomal pathway is dysregulated by APOE4 expression in vivo. Front. Neurosci. 11, 702 (2017).
Xian, X. et al. Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer’s disease. eLife 7, 7779 (2018).
Zhao, N. et al. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron 96, 115.e5–129.e5 (2017).
Prasad, H. & Rao, R. Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH. Proc. Natl Acad. Sci. USA 115, E6640–E6649 (2018).
Egensperger, R., Kösel, S., Eitzen, von, U. & Graeber, M. B. Microglial activation in Alzheimer disease: association with APOE genotype. Brain Pathol. 8, 439–447 (1998).
Vitek, M. P., Brown, C. M. & Colton, C. A. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging 30, 1350–1360 (2009).
Abner, E. L. et al. Diffuse amyloid-β plaques, neurofibrillary tangles, and the impact of ApoE in elderly persons’ brains lacking neuritic amyloid plaques. J. Alzheimers Dis. 64, 1307–1324 (2018).
Bell, W. R. et al. Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer’s disease. Alzheimers Dement. 15, 8–16 (2018).
McMillan, C. T. et al. Alzheimer’s genetic risk is reduced in primary age-related tauopathy: a potential model of resistance? Ann. Clin. Transl. Neurol. 5, 927–934 (2018).
Efthymiou, A. G. & Goate, A. M. Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 12, 43 (2017).
van der Lee, S. J. et al. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathol. 138, 237–250 (2019).
Olah, M. et al. A transcriptomic atlas of aged human microglia. Nat. Commun. 9, 539 (2018).
Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169, 1276.e17–1290.e17 (2017).
Krasemann, S. et al. The TREM2–APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566.e9–581.e9 (2017).
Hansen, D. V., Hanson, J. E. & Sheng, M. Microglia in Alzheimer’s disease. J. Cell Biol. 217, 459–472 (2018).
Asai, H. et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18, 1584–1593 (2015).
Luo, W. et al. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci. Rep. 5, 11161 (2015).
Maphis, N. et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain 138, 1738–1755 (2015).
Bhaskar, K. et al. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68, 19–31 (2010). This is one of the first studies to show that the activation of microglia (in the absence of Aβ) suffices to promote hyperphosphorylation of tau in neurons of tau-transgenic mice.
Leyns, C. E. G. & Holtzman, D. M. Glial contributions to neurodegeneration in tauopathies. Mol. Neurodegener. 12, 50 (2017).
Meda, L. et al. Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 374, 647–650 (1995).
Jiang, T. et al. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. Neuropharmacology 105, 196–206 (2016).
Jiang, T. et al. Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice. Neurobiol. Aging 36, 3176–3186 (2015).
Bemiller, S. M. et al. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol. Neurodegener. 12, 74 (2017).
Leyns, C. E. G. et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl Acad. Sci. USA 114, 11524–11529 (2017).
Moore, S. et al. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep. 11, 689–696 (2015).
Muratore, C. R. et al. The familial Alzheimer’s disease APPV717I mutation alters APP processing and tau expression in iPSC-derived neurons. Hum. Mol. Genet. 23, 3523–3536 (2014).
Shi, Y. et al. A human stem cell model of early Alzheimer’s disease pathology in Down syndrome. Sci. Transl Med. 4, 124ra29 (2012).
Israel, M. A. et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature 482, 216–220 (2012).
Sasaguri, H. et al. APP mouse models for Alzheimer’s disease preclinical studies. EMBO J. 36, 2473–2487 (2017).
Cataldo, A. M. et al. App gene dosage modulates endosomal abnormalities of Alzheimer’s disease in a segmental trisomy 16 mouse model of Down syndrome. J. Neurosci. 23, 6788–6792 (2003).
Hung, C. O. Y. & Livesey, F. J. Altered γ-secretase processing of APP disrupts lysosome and autophagosome function in monogenic Alzheimer’s disease. Cell Rep. 25, 3647.e2–3660.e2 (2018).
Kim, S. et al. Evidence that the rab5 effector APPL1 mediates APP-βCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer’s disease. Mol. Psychiatry 21, 707–716 (2016).
Woodruff, G. et al. Defective transcytosis of APP and lipoproteins in human iPSC-derived neurons with familial Alzheimer’s disease mutations. Cell Rep. 17, 759–773 (2016).
Kwart, D. et al. A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP β-CTFs, not Aβ. Neuron 104, 256–270 (2019).
Karran, E. & De Strooper, B. The amyloid cascade hypothesis: are we poised for success or failure? J. Neurochem. 139, 237–252 (2016).
Nicoll, J. A. R. et al. Aβ species removal after Aβ42 immunization. J. Neuropathol. Exp. Neurol. 65, 1040–1048 (2006).
Nicoll, J. A. R. et al. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease. Brain 142, 2113–2126 (2019).
Mattsson, N. et al. 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. EMBO Mol. Med. 9, 1212–1223 (2017).
Buerger, K. et al. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 130, e82–e82 (2007).
Smith, R., Wibom, M., Pawlik, D., Englund, E. & Hansson, O. Correlation of in vivo [18F]-flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol. 76, 310–317 (2019). This study shows a strong correspondence between in vivo tau PET findings and postmortem tau pathology in a patient with familial AD.
Southekal, S. et al. Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity. J. Nucl. Med. 59, 944–951 (2018).
Devous, M. D. et al. Test-retest reproducibility for the tau PET imaging agent flortaucipir F18. J. Nucl. Med. 59, 937–943 (2018).
Sperling, R. A. et al. The A4 study: stopping AD before symptoms begin? Sci. Transl Med. 6, 228fs13 (2014).
Congdon, E. E. & Sigurdsson, E. M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 14, 399–415 (2018).
Yamazaki, Y., Painter, M. M., Bu, G. & Kanekiyo, T. Apolipoprotein E as a therapeutic target in Alzheimer’s disease: a review of basic research and clinical evidence. CNS Drugs 30, 773–789 (2016).
Gupta, V. B. et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76, 1091–1098 (2011).
Cramer, P. E. et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335, 1503–1506 (2012).
Boehm-Cagan, A. & Michaelson, D. M. Reversal of ApoE4-driven brain pathology and behavioral deficits by bexarotene. J. Neurosci. 34, 7293–7301 (2014).
Veeraraghavalu, K. et al. Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”. Science 340, 924–992 (2013).
Tesseur, I. et al. Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”. Science 340, 924–992 (2013).
Price, A. R. et al. Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”. Science 340, 924–992 (2013).
Cummings, J. L. et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease. Alzheimers Res. Ther. 8, 4 (2016).
Ye, S. et al. Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl Acad. Sci. USA 102, 18700–18705 (2005).
Brodbeck, J. et al. Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J. Biol. Chem. 286, 17217–17226 (2011).
E·Scape Bio. ApoE4 is the strongest genetic risk factor for late-onset Alzheimer’s disease. Individuals carry one of three variants of the ApoE gene: ApoE2, ApoE3, or ApoE4. E⋅Scape Bio http://www.e-scapebio.com/science/index.php (2019).
Neefjes, J. & van der Kant, R. Stuck in traffic: an emerging theme in diseases of the nervous system. Trends Neurosci. 37, 66–76 (2014).
Small, S. A. et al. Model-guided microarray implicates the retromer complex in Alzheimer’s disease. Ann. Neurol. 58, 909–919 (2005).
Qureshi, Y. H. et al. Retromer repletion with AAV9–VPS35 restores endosomal function in the mouse hippocampus. Alzheimers Dement. 15, 1597–1598 (2019).
Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358–378 (2019).
Li, Q. & Barres, B. A. Microglia and macrophages in brain homeostasis and disease. Nat. Rev. Immunol. 18, 225–242 (2018).
Lee, S. et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer’s disease mouse models. Am. J. Pathol. 177, 2549–2562 (2010).
Liu, Z., Condello, C., Schain, A., Harb, R. & Grutzendler, J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-β phagocytosis. J. Neurosci. 30, 17091–17101 (2010).
Xiang, X. et al. The Trem2 R47H Alzheimer’s risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans. Mol. Neurodegener. 13, 49 (2018).
Alam, J., Blackburn, K. & Patrick, D. Neflamapimod: clinical phase 2b-ready oral small molecule inhibitor of p38α to reverse synaptic dysfunction in early Alzheimer’s disease. J. Prev. Alzheimers Dis. 4, 273–278 (2017).
Scheltens, P. et al. An exploratory clinical study of p38α kinase inhibition in Alzheimer’s disease. Ann. Clin. Transl. Neurol. 5, 464–473 (2018).
Bachstetter, A. D. et al. Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by Toll-like receptor (TLR) ligands or beta-amyloid (Aβ). J. Neuroinflammation 8, 79 (2011).
Sims, R. et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat. Genet. 49, 1373–1384 (2017).
Shinohara, M. et al. Reduction of brain beta-amyloid (Aβ) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Aβ clearance. J. Biol. Chem. 285, 22091–22102 (2010).
Kurata, T. et al. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res. 1371, 161–170 (2011).
Zissimopoulos, J. M., Barthold, D., Brinton, R. D. & Joyce, G. Sex and race differences in the association between statin use and the incidence of Alzheimer disease. JAMA Neurol. 74, 225–232 (2017).
Shepardson, N. E., Shankar, G. M. & Selkoe, D. J. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch. Neurol. 68, 1239–1244 (2011).
Shepardson, N. E., Shankar, G. M. & Selkoe, D. J. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch. Neurol. 68, 1385–1392 (2011).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00842920 (2019).
Vega, G. L. & Weiner, M. F. Plasma 24S hydroxycholesterol response to statins in Alzheimer’s disease patients: effects of gender, CYP46, and ApoE polymorphisms. J. Mol. Neurosci. 33, 51–55 (2007).
Serrano-Pozo, A. et al. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis. Assoc. Disord. 24, 220–226 (2010).
Li, G. et al. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults. Neurology 89, 1251–1255 (2017).
Riekse, R. G. et al. Effect of statins on Alzheimer’s disease biomarkers in cerebrospinal fluid. J. Alzheimers Dis. 10, 399–406 (2006).
Mast, N. et al. Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice. J. Biol. Chem. 289, 3529–3538 (2014).
Mast, N. et al. Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer’s disease. Neuropharmacology 123, 465–476 (2017). This study first identifies small molecules (including efavirenz) that act as allosteric activators of CYP46A1 and specifically regulate neuronal cholesterol metabolism.
Mast, N. et al. In vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds. J. Biol. Chem. 292, 12934–12946 (2017).
Anderson, K. W. et al. Mapping of the allosteric site in cholesterol hydroxylase CYP46A1 for efavirenz, a drug that stimulates enzyme activity. J. Biol. Chem. 291, 11876–11886 (2016).
Petrov, A. M. et al. CYP46A1 activation by Efavirenz leads to behavioral improvement without significant changes in amyloid plaque load in the brain of 5XFAD mice. Neurotherapeutics 15, 1–15 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03706885 (2019).
Hudry, E. et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s disease. Mol. Ther. 18, 44–53 (2010).
Huttunen, H. J. & Kovacs, D. M. ACAT as a drug target for Alzheimer’s disease. Neurodegener. Dis. 5, 212–214 (2008).
Santacruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476–481 (2005). This is the first study to show that reducing tau expression in tau transgenic mice can rescue neuronal loss and behavioural deficits, even when extensive neurofibrillary tangles are already present.
Busche, M. A. et al. Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo. Nat. Neurosci. 22, 57–64 (2019).
DeVos, S. L. et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl Med. 9, eaag0481 (2017).
DeVos, S. L. et al. Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo. Brain 141, 2194–2212 (2018).
Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487–1491 (2001).
Oddo, S. et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39, 409–421 (2003).
Lauritzen, I. et al. Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology. Acta Neuropathol. 132, 257–276 (2016).
Barthet, G. et al. Presenilin-mediated cleavage of APP regulates synaptotagmin-7 and presynaptic plasticity. Nat. Commun. 9, 4780 (2018).
Mondragón-Rodríguez, S., Gu, N., Manseau, F. & Williams, S. Alzheimer’s transgenic model is characterized by very early brain network alterations and β-CTF fragment accumulation: reversal by β-secretase inhibition. Front. Cell. Neurosci. 12, 121 (2018).
Kim, J. et al. Normal cognition in transgenic BRI2–Aβ mice. Mol. Neurodegener. 8, 15 (2013).
Götz, J., Chen, F., van Dorpe, J. & Nitsch, R. M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ 42 fibrils. Science 293, 1491–1495 (2001).
Bolmont, T. et al. Induction of tau pathology by intracerebral infusion of amyloid-β-containing brain extract and by amyloid-βdeposition in APP×tau transgenic mice. Am. J. Pathol. 171, 2012–2020 (2007).
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H. & LaFerla, F. M. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321–332 (2004).
Oddo, S. et al. Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281, 39413–39423 (2006).
Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698–712 (2011).
Fong, L. K. et al. Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-β clearance in human astrocytes. J. Biol. Chem. 293, 11341–11357 (2018).
Garcia-Reitboeck, P. et al. Human induced pluripotent stem cell-derived microglia-like cells harboring TREM2 missense mutations show specific deficits in phagocytosis. Cell Rep. 24, 2300–2311 (2018).
Young, J. E. et al. Elucidating molecular phenotypes caused by the SORL1 Alzheimer’s disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell 16, 373–385 (2015).
Meyer, K. et al. REST and neural gene network dysregulation in iPSC models of Alzheimer’s disease. Cell Rep. 26, 1112.e9–1127.e9 (2019).
Kondo, T. et al. iPSC-based compound screening and in vitro trials identify a synergistic anti-amyloid β combination for Alzheimer’s disease. Cell Rep. 21, 2304–2312 (2017).
Brownjohn, P. W. et al. Phenotypic screening identifies modulators of amyloid precursor protein processing in human stem cell models of Alzheimer’s disease. Stem Cell Rep. 8, 870–882 (2017).
Kondo, T. et al. Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell 12, 487–496 (2013).
Yang, N. et al. Generation of pure GABAergic neurons by transcription factor programming. Nat. Methods 14, 621–628 (2017).
Zhang, Y. et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785–798 (2013).
Meijer, M. et al. A single-cell model for synaptic transmission and plasticity in human iPSC-derived neurons. Cell Rep. 27, 2199.e6–2211.e6 (2019).
Choi, S. H. et al. A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature 515, 274–278 (2014).
Espuny-Camacho, I. et al. Hallmarks of Alzheimer’s disease in stem-cell-derived human neurons transplanted into mouse brain. Neuron 93, 1066.e8–1081.e8 (2017).
Huttunen, H. J. et al. Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J. 23, 3819–3828 (2009).
The authors thank P. Scheltens, J. Young and P. van Bokhoven for discussion and critical reading of the manuscript, and D. Berron for assistance with figure preparation. R.v.d.K. is supported by an Alzheimer Netherlands Pilot Grant (WE.-3-2017-09) and by a Weston Brain Institute Rapid Response Netherlands Grant (NR170059). L.S.B.G. is supported by National Institute on Ageing (NIA) grant 1RF1AG048083-01 and by California Institute for Regenerative Medicine (CIRM) RB5-07011 grants.
The authors declare no competing interests.
Peer review information
Nature Reviews Neuroscience thanks J. Avila and the other, anonymous, reviewers for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Neurofibrillary tangles
(NFTs). Intraneuronal aggregates of hyperphosphorylated tau abnormally folded into paired helical filaments. Tau pathology develops late in the progression of Alzheimer disease, and its severity correlates well with cognitive impairment and local neurodegeneration.
- Mild cognitive impairment
(MCI). A clinical state characterized by objective cognitive impairment that does not interfere with daily functioning and is insufficient for the diagnosis of dementia. Patients with amyloid-β (positron emission tomography or cerebrospinal fluid) biomarker positivity are considered to have MCI due to Alzheimer disease.
- Aβ immunoclearance
Pharmaceutical intervention aimed at clearing amyloid-β plaques and/or oligomerized peptides from the brains of patients with Alzheimer disease. Has been the major focus for the development of treatments for Alzheimer disease.
- Positron emission tomography
(PET). Functional imaging technique that measures gamma rays emitted by radioactively labelled tracers and is used to track biological processes in vivo. Several PET tracers for amyloid-β and tau have been developed that can measure Alzheimer disease pathology in living individuals.
- Aβ plaques
Aggregates of amyloid-β (Aβ) protein that accumulate extracellularly in individuals with Alzheimer disease. Aβ plaques (also known as neuritic or senile plaques) develop early in the course of Alzheimer disease but do not correlate well with cognitive decline or local neurodegeneration.
- Primary age-related tauopathy
(PART). A neuropathological condition characterized by neurofibrillary tangles, restricted mostly to the temporal lobe in the absence of amyloid-β; evident in the brains of approximately 20% of cognitively normal elderly individuals.
- β-secretase C-terminal fragment of APP
(βCTF). Direct precursor of amyloid-β (Aβ) that is generated by β-secretase cleavage of full-length amyloid precursor protein, prior to its γ-secretase cleavage to Aβ. Aβ and βCTF are therefore generated at equimolar concentration. βCTF drives the accumulation of phosphorylated tau in neurons from patients with familial Alzheimer disease.
Genetic variants that occur in at least 1% of the population; rare variants occur at frequencies below 1%.
- Proteasomal degradation
The process by which cells recycle unneeded or damaged cytosolic proteins. Such proteins are first ubiquitylated, which targets them for degradation by the proteasome (a proteolytic multisubunit protein complex).
- Endocytic system
An interconnected network of membranous vesicles that internalize molecules from the plasma membrane and transport them through the cell. Depending on the specific route of transport, molecules can be degraded in lysosomes or recycled back to the surface.
A multiprotein sorting complex on early endosomes that redirects cargo molecules (such as amyloid precursor protein) from the endosome to the trans-Golgi network or the plasma membrane, which prevents their trafficking into the late endocytic system where they can be degraded.
- Disease-associated microglia
A subset of activated microglia found at sites of neurodegeneration.
- Adeno-associated virus
(AAV). A small virus that infects humans without causing disease and that can be engineered to deliver target genes into humans (gene therapy).
About this article
Cite this article
van der Kant, R., Goldstein, L.S.B. & Ossenkoppele, R. Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci 21, 21–35 (2020). https://doi.org/10.1038/s41583-019-0240-3
This article is cited by
PDZD8-deficient mice manifest behavioral abnormalities related to emotion, cognition, and adaptation due to dyslipidemia in the brain
Molecular Brain (2023)
Molecular Neurodegeneration (2023)
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
Alzheimer's Research & Therapy (2022)
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases
Molecular Neurodegeneration (2022)
An App knock-in rat model for Alzheimer’s disease exhibiting Aβ and tau pathologies, neuronal death and cognitive impairments
Cell Research (2022)